4670-09-1

Basic information

• Product Name: 3,5-Dihdyroxyphenylacetic acid
• Synonyms: 3,5-DIHYDROXY BENZENEACETIC ACID;3,5-Dihdyroxyphenylacetic acid;3,5-DIHYDROXYPHENYLACETIC ACID;3,5-Dihydroxy;3,5-Dihydroxylphenylacetic acid;2-(3,5-Dihydroxyphenyl)acetic acid;2-(3,5-Dihydroxyphenyl)
• CAS NO: 4670-09-1
• Molecular Formula: C₈H₈O₄
• Molecular Weight: 168.15
• Product Categories: Aromatic Phenylacetic Acids and Derivatives;Organic acids
• Mol File: 4670-09-1.mol

Chemical Properties

• Melting Point: 126-127 °C
• Boiling Point: 416.1°Cat760mmHg
• Flash Point: 219.6°C
• Appearance: /
• Density: 1.478g/cm³
• Vapor Pressure: 1.14E-07mmHg at 25°C
• Refractive Index: 1.642
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.12±0.10(Predicted)
• CAS DataBase Reference: 3,5-Dihdyroxyphenylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dihdyroxyphenylacetic acid(4670-09-1)
• EPA Substance Registry System: 3,5-Dihdyroxyphenylacetic acid(4670-09-1)

Safety Data

• Hazardous Substances Data: 4670-09-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,5-Dihydroxyphenylacetic acid is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure makes it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Neuroprotective Agents:
3,5-Dihydroxyphenylacetic acid is involved in the discovery of KLS-13019, a cannabidiol-derived neuroprotective agent. 3,5-Dihdyroxyphenylacetic acid has shown potential in protecting neurons from damage and may be useful in the treatment of neurodegenerative diseases.
Used in Metabolite Research:
As a major metabolite of myricetin, 3,5-dihydroxyphenylacetic acid is relevant in the study of the metabolic pathways and biological effects of this flavonoid. Myricetin is a naturally occurring compound found in various fruits and vegetables, and it has been linked to several health benefits, including antioxidant and anti-inflammatory properties.

InChI:InChI=1/C8H8O4/c9-6-1-5(3-8(11)12)2-7(10)4-6/h1-2,4,9-10H,3H2,(H,11,12)

Upstream product

• 6202-45-5 ethyl-2,4-di(ethoxycarbonyl)-3,5-dihydroxyphenylacetate 
• 13388-75-5 3,5-dimethoxyphenylacetonitrile 
• 6512-25-0 dimethyl 2,4-dihydroxy-6-(2-methoxy-2-oxoethyl)benzene-1,3-dicarboxylate 
• 705-76-0 3,5-dimethoxybenzyl alcohol 
• 6652-32-0 3,5-dimethoxybenzylchloride 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 4670-10-4 (3,5-dimethoxyphenyl)acetic acid 

Downstream Products

• 4670-10-4 (3,5-dimethoxyphenyl)acetic acid 
• 65976-77-4 (3,5-dimethoxy-phenyl)-acetic acid ethyl ester 
• 4724-10-1 methyl 2-(3,5-dihydroxyphenyl)acetate 
• 2732-96-9 3,5-dibenzyloxyphenylacetic acid 
• 6512-32-9 methyl 2-(3,5-dimethoxyphenyl)acetate 
• 63720-56-9 α-(3,5-Diacetoxyphenyl)-3,4,5-trimethoxyzimtsaeure 
• 501-36-0 (E)-5-[2-4-(hydroxyphenyl)ethenyl]-1,3-benzenediol 
• 80907-81-9 N-(3-methoxyphenethyl)-2-<3,5-bis(benzyloxy)phenyl>acetamide 
• 79087-59-5 1-<3',5-bis(benzyloxy)benzyl>-6-methoxy-3,4-dihydroisoquinoline 
• 76787-08-1 1-(3',5'-dibenzyloxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 135387-90-5 (S)-4-Benzyl-3-[2-(3,5-dimethoxy-phenyl)-acetyl]-oxazolidin-2-one 
• 135388-00-0 methyl 1,3-bis(tert-butyldimethylsilyloxy)phenylacetate 
• 135388-01-1 [3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-acetic acid tert-butyl ester 
• 135388-03-3 Amino-[3,5-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-acetic acid tert-butyl ester 

Relevant articles and documents

Preparation and application of (Z)-3,5-dihydroxy-4-isopropylstilbene

The invention discloses a preparation method and application of (Z)-3,5-dihydroxy-4-isopropylstilbene. According to the preparation method, a raw material, namely 3,5-dihydroxy-2,4-diethoxycarbonyl ethyl phenylacetate as an initiator, hydrolysis decarboxy

Xylochemical synthesis and biological evaluation of shancigusin c and bletistrin g

The biological activities of shancigusin C (1) and bletistrin G (2), natural products isolated from orchids, are reported along with their first total syntheses. The total synthesis of shancigusin C (1) was conducted by employing the Perkin reaction to forge the central stilbene core, whereas the synthesis of bletistrin G (2) was achieved by the Wittig olefination followed by several regiose-lective aromatic substitution reactions. Both syntheses were completed by applying only renewable starting materials according to the principles of xylochemistry. The cytotoxic properties of shancigusin C (1) and bletistrin G (2) against tumor cells suggest suitability as a starting point for further structural variation.

Synthesis method of (E)-3,5-dihydroxy-4-isopropyl stilbene

The invention discloses a synthesis method of (E)-3,5-dihydroxy-4-isopropyl stilbene, which comprises the following steps: by using a biomass-derived raw material 3,5-dihydroxy-2,4-diethoxycarbonyl ethyl phenylacetate as an initiator, carrying out hydrolysis decarboxylation, isopropylation, condensation, decarboxylation, isomerization and other reaction steps to synthesize the (E)-3,5-dihydroxy-4-isopropyl stilbene. In the invention, the biomass derivative raw materials can be adopted as initiators, operation is easy and convenient, the steps are simple and convenient, functional group protection and deprotection are not needed, and atom economy is good; the intermediate can be put into the next step of reaction without complex separation and purification, so that large-scale preparation is facilitated; and the generated excessive waste acid and catalyst compound can be recycled, so that the cost of the technological process is reduced, the emission is reduced, and the method is greenand environment-friendly.

First total synthesis of medicinally important 3,4,7-trimethoxy-9,10-dihydrophenanthrene-1,5-diol

The first total synthesis was successfully achieved for biologically active 9,10-dihydrophenanthrene-1,5-diol. The key features of our synthetic approach are Perkin condensation, followed by bromination, palladium mediated intramolecular C-C bond coupling, and selective isopropyl ether cleavage. Synthesized compounds were purified and characterized by IR, 1HNMR, 13CNMR and HRMS/LC-MS.

Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability

Cannabidiol is the nonpsychoactive natural component of C. sativa that has been shown to be neuroprotective in multiple animal models. Our interest is to advance a therapeutic candidate for the orphan indication hepatic encephalopathy (HE). HE is a serious neurological disorder that occurs in patients with cirrhosis or liver failure. Although cannabidiol is effective in models of HE, it has limitations in terms of safety and oral bioavailability. Herein, we describe a series of side chain modified resorcinols that were designed for greater hydrophilicity and "drug likeness", while varying hydrogen bond donors, acceptors, architecture, basicity, neutrality, acidity, and polar surface area within the pendent group. Our primary screen evaluated the ability of the test agents to prevent damage to hippocampal neurons induced by ammonium acetate and ethanol at clinically relevant concentrations. Notably, KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol and exhibited an in vitro profile consistent with improved oral bioavailability.

Controlled-deactivation cannabinergic ligands

We report an approach for obtaining novel cannabinoid analogues with controllable deactivation and improved druggability. Our design involves the incorporation of a metabolically labile ester group at the 2′-position on a series of (-)-Δ8-THC a

A diastereoselective formal synthesis of berkelic acid

A formal synthesis of berkelic acid is reported. The strategy employs the combination of a chiral exocyclic enol ether and an achiral isochromanone to afford the chroman spiroketal core via a base-triggered generation and cycloaddition of an o-quinone met

PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS

The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

Melanin Biosynthesis: A Study of Polyphenol Deoxygenation

The 1,3,6,8-Tetrahydroxynaphthalene (T4HN) reductase of Verticillium dahliae has been studied in a cell-free system.The use of specifically labelled 4(R)- and NADPH in the reduction of T4HN to scytalone reveals that the l